Wednesday, April 12, 2006

How is the antiphospholipid syndrome treated?

How is the antiphospholipid syndrome treated?

The treatment of patients with anticardiolipin syndrome has substantially evolved since they were discovered to be clinically important in the mid-1980s. Each manifestation of the antiphospholipid syndrome, and each individual patient with the condition, is treated uniquely.

Because many of the features of illness with anticardiolipin syndrome are associated with an abnormal grouping of normal blood clotting elements (platelets), treatment is often directed toward preventing clotting by thinning the blood. Patients with this disorder have an abnormal tendency to form blood clots (thrombosis). The abnormal blood clotting can affect the function of virtually any organ. Medications that thin (anticoagulate) the blood, such as heparin and coumadin (powerful blood thinners), are used for treatment. Aspirin has an affect on platelets which inhibits their grouping (aggregation) and has also been used in low doses to thin the blood of selected patients. Cortisone-related medications, such as prednisone, have been used to suppress the immune activity and inflammation in patients with certain features of the condition. For patients with systemic lupus erythematosus who also have anticardiolipin syndrome, hydroxychloroquine (Plaquenil) has been reported to add some protection against blood clotting.

Other reported treatments include the use of intravenous gamma globulin for selected patients with histories of premature miscarriage and those with low blood-clotting elements (platelets) during pregnancy. Recent research studies, however, suggest that intravenous gamma globulin may be no more effective than combination aspirin and heparin treatment.

http://www.medicinenet.com/antiphospholipid_syndrome/page2.htm

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home

Creative Commons License
Antiphospholipid Antibody Syndrome by APS Foundation of America, Inc is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.
Based on a work at www.apsfa.org.